novo nordisk glp 1 asks FDA to prevent compounders from making GLP-1 knockoffs Novo Nordisk plans to slash

With increasing frequency over the past few years, optometrists across the country have gotten referrals from internists requesting baseline diabetic retinopathy (DR) screenings for patients about to start therapy with one of the glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists such as semaglutide (Ozempic, Novo Nordisk), tirzepatide (Mounjaro, Eli Lilly) and dulaglutide (Trulicity, Eli Lilly

While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation

GLP-1 injections like Mounjaro, Wegovy, Ozempic, and Zepbound let our body hack the system

After 1 hour, the blood glucose levels were measured immediately before administering a high dose of glucose by IP injection

The study revealed that those taking these semaglutide-based drugs for weight loss were seven times more likely to experience the condition than those on other obesity treatments